2024 | | A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study) | 김혜진 |
2024 | | HDAC11 Regulates Palmitate-induced NLRP3 Inflammasome Activation by Inducing YAP Expression in THP-1 Cells and PBMCs | 모정순, 변혜은, 전자영, 최성이 |
2024 | | Impact of diabetes distress on glycemic control and diabetic complications in type 2 diabetes mellitus | 이관우 |
2024 | | Higher HbA1c Is Associated With Greater 2-Year Progression of White Matter Hyperintensities | 노현웅, 문소영, 박범희, 손상준, 안영실, 정재연, 조용혁, 최진욱, 한승진, 홍창형 |
2024 | | Effectiveness and safety of sodium–glucose cotransporter 2 inhibitors in Asian populations | 김대중, 하경화 |
2024 | | Imeglimin attenuates NLRP3 inflammasome activation by restoring mitochondrial functions in macrophages | 김대중, 김혜진, 이관우, 전자영, 한승진 |
2024 | | Lower Atrial Fibrillation Risk With Sodium-Glucose Cotransporter 2 Inhibitors Than With Dipeptidyl Peptidase-4 Inhibitors in Individuals With Type 2 Diabetes: A Nationwide Cohort Study | 김대중, 하경화 |
2024 | | Effect of Pravastatin on Kidney Function in Patients with Dyslipidemia and Type 2 Diabetes Mellitus: A Multicenter Prospective Observational Study | 김혜진 |
2024 | | Efficacy and Safety of Metformin and AtorvastatinCombination Therapy vs. Monotherapy with EitherDrug in Type 2 Diabetes Mellitus and DyslipidemiaPatients (ATOMIC): Double-Blinded RandomizedControlled Trial | 김대중 |
2024 | | The Association of Smoking Status with Diabetic Microvascular Complications in Korean Patients with Type 2 Diabetes | 이관우 |
2024 | | Comparative effectiveness and safety outcomes between denosumab and bisphosphonate in South Korea | 박래웅, 전자영 |
2024 | | Cysteine-rich 61 inhibition attenuates hepatic insulin resistance and improves lipid metabolism in high-fat diet fed mice and HepG2 cells | 김대중, 김혜진, 이관우, 이나미, 전자영, 최성이, 한승진, 허유정 |
2024 | | 2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association | 김대중, 김혜진 |
2024 | | Financial Benefits of Renal Dose-Adjusted Dipeptidyl Peptidase-4 Inhibitors for Patients with Type 2 Diabetes and Chronic Kidney Disease | 김대중, 하경화 |
2024 | | Acute Suppurative Thyroiditis as a Presentation of Disseminated Methicillin-Resistant Staphylococcus aureus Infection in an Adult with Type 1 Diabetes | 이나미, 전자영, 최용준, 한승진 |
2024 | | Cancer treatment-induced bone loss | 최용준 |
2024 | | Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus | 김대중, 전자영 |
2024 | | Efficacy and safety of dapagliflozin add-on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study | 한승진 |
2023 | | Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study | 김대중, 하경화 |
2023 | | Diabetes screening in South Korea: a new estimate of the number needed to screen to detect diabetes | 김대중, 하경화 |
2023 | | Asia–pacific consensus on osteoporotic fracture prevention in postmenopausal women with low bone mass or osteoporosis but no fragility fractures | 정윤석 |
2023 | | Ultra-Processed Food Consumption and Obesity in Korean Adults | 김대중, 하경화 |
2023 | | Associations of updated cardiovascular health metrics, including sleep health, with incident diabetes and cardiovascular events in older adults with prediabetes: A nationwide population-based cohort study | 김대중, 하경화, 한승진 |
2023 | | Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia | 김대중, 하경화 |
2023 | | Impact of prolonged carbapenem use-focused antimicrobial stewardship on antimicrobial consumption and factors affecting acceptance of recommendations: a quasi-experimental study | 김영롱, 김은진, 유진세, 최영화, 하경화, 허중연 |
2023 | | Cardiovascular Outcomes according to Comorbidities and Low-Density Lipoprotein Cholesterol in Korean People with Type 2 Diabetes Mellitus | 김혜진 |
2023 | | Diet quality partially mediates the association between ultraprocessed food consumption and adiposity indicators | 김대중, 하경화 |
2023 | | Long-term Effectiveness of the National Diabetes Quality Assessment Program in South Korea | 김대중, 하경화 |
2023 | | Association between Low-Density Lipoprotein Cholesterol Level and Cardiovascular Outcomes in Korean Adults: A Nationwide Cohort Study | 김혜진 |
2023 | | Impact of Post-Transplant Diabetes Mellitus on Survival and Cardiovascular Events in Kidney Transplant Recipients | 김대중, 김혜진, 박범희, 이관우, 전자영, 한승진 |
2023 | | Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study | 김대중, 하경화 |
2023 | | Effects of dapagliflozin compared with glimepiride on body composition in Asian patients with type 2 diabetes inadequately controlled with metformin: The BEYOND study | 이관우 |
2023 | | In-depth proteomic signature of parathyroid carcinoma | 최용준 |
2023 | | Changes in glucose metabolism among recipients with diabetes 1 year after kidney transplant: a multicenter 1-year prospective study | 방준배, 오창권, 이수형, 전자영 |
2023 | | Lower risk of cardiovascular events and death associated with initiation of sodium-glucose cotransporter-2 inhibitors versus sulphonylureas: Analysis from the CVD-REAL 2 study | 김대중 |
2023 | | UBAP2 plays a role in bone homeostasis through the regulation of osteoblastogenesis and osteoclastogenesis | 김범택, 김정현, 박은국, 원예연, 정선용, 정윤석, 최용준 |
2023 | | Amphiregulin Induces iNOS and COX-2 Expression through NF- κ B and MAPK Signaling in Hepatic Inflammation | 강엽, 김대중, 김혜진, 이관우, 이나미, 전자영, 최성이, 한승진, 허유정 |
2023 | | 2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association | 김대중, 김혜진 |
2023 | | Effect of statin use on head and neck cancer prognosis in a multicenter study using a Common Data Model | 김철호, 박래웅, 신유섭, 장전엽, 전자영 |
2023 | | Protective effect of empagliflozin against palmitate-induced lipotoxicity through AMPK in H9c2 cells | 강엽, 김혜진, 이관우, 전자영, 최성이 |
2023 | | Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension | 김혜진 |
2022 | | Short-Term Air Pollution Exposure and Risk of Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Korea: A National Time-Stratified Case-Crossover Study | 김대중, 김은진, 정윤정, 최영화, 하경화, 허중연 |
2022 | | Gene Network Analysis for Osteoporosis, Sarcopenia, Diabetes, and Obesity in Human Mesenchymal Stromal Cells | 정윤석, 최용준 |
2022 | | Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study | 김혜진 |
2022 | | A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus | 한승진 |
2022 | | Performance of Diabetes and Kidney Disease Screening Scores in Contemporary United States and Korean Populations | 김대중 |
2022 | | Screening for Prediabetes and Diabetes in Korean Nonpregnant Adults: A Position Statement of the Korean Diabetes Association, 2022 | 김대중 |
2022 | | Rising Incidence of Diabetes in Young Adults in South Korea: A National Cohort Study | 김대중, 하경화 |
2022 | | Trends and Risk Factors of Metabolic Syndrome among Korean Adolescents, 2007 to 2018 (Diabetes Metab J 2021;45:880-9) | 김대중 |
2022 | | The Positive Association between Muscle Mass and Bone Status Is Conserved in Men with Diabetes: A Retrospective Cross-Sectional and Longitudinal Study | 김대중, 김혜진, 정윤석, 최용준, 한승진 |